The application of multiple markers, including mammaglobin, cytokeratin 19, and carcinoembryonic antigen (CEA), has been proposed for guiding surgical decisions on axillary lymph node dissection in breast cancer [69,70]. This evidence concerns the gene CEACAM5 and breast carcinoma.